These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 21288472)
1. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Chung YC; Kim SR; Park JY; Chung ES; Park KW; Won SY; Bok E; Jin M; Park ES; Yoon SH; Ko HW; Kim YS; Jin BK Neuropharmacology; 2011 May; 60(6):963-74. PubMed ID: 21288472 [TBL] [Abstract][Full Text] [Related]
2. Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. Chung YC; Bok E; Huh SH; Park JY; Yoon SH; Kim SR; Kim YS; Maeng S; Park SH; Jin BK J Immunol; 2011 Dec; 187(12):6508-17. PubMed ID: 22079984 [TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation. Moon M; Kim HG; Hwang L; Seo JH; Kim S; Hwang S; Kim S; Lee D; Chung H; Oh MS; Lee KT; Park S Neurotox Res; 2009 May; 15(4):332-47. PubMed ID: 19384567 [TBL] [Abstract][Full Text] [Related]
4. Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease. Huh SH; Chung YC; Piao Y; Jin MY; Son HJ; Yoon NS; Hong JY; Pak YK; Kim YS; Hong JK; Hwang O; Jin BK J Immunol; 2011 Jul; 187(2):960-9. PubMed ID: 21685323 [TBL] [Abstract][Full Text] [Related]
5. Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity. Zhang D; Hu X; Wei SJ; Liu J; Gao H; Qian L; Wilson B; Liu G; Hong JS J Neuroinflammation; 2008 May; 5():21. PubMed ID: 18507839 [TBL] [Abstract][Full Text] [Related]
6. Capsaicin prevents degeneration of dopamine neurons by inhibiting glial activation and oxidative stress in the MPTP model of Parkinson's disease. Chung YC; Baek JY; Kim SR; Ko HW; Bok E; Shin WH; Won SY; Jin BK Exp Mol Med; 2017 Mar; 49(3):e298. PubMed ID: 28255166 [TBL] [Abstract][Full Text] [Related]
7. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260 [TBL] [Abstract][Full Text] [Related]
8. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. Chung YC; Kim SR; Jin BK J Immunol; 2010 Jul; 185(2):1230-7. PubMed ID: 20566832 [TBL] [Abstract][Full Text] [Related]
9. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Du Y; Ma Z; Lin S; Dodel RC; Gao F; Bales KR; Triarhou LC; Chernet E; Perry KW; Nelson DL; Luecke S; Phebus LA; Bymaster FP; Paul SM Proc Natl Acad Sci U S A; 2001 Dec; 98(25):14669-74. PubMed ID: 11724929 [TBL] [Abstract][Full Text] [Related]
10. Fluoxetine prevents LPS-induced degeneration of nigral dopaminergic neurons by inhibiting microglia-mediated oxidative stress. Chung ES; Chung YC; Bok E; Baik HH; Park ES; Park JY; Yoon SH; Jin BK Brain Res; 2010 Dec; 1363():143-50. PubMed ID: 20858471 [TBL] [Abstract][Full Text] [Related]
11. Tanshinone IIA prevents the loss of nigrostriatal dopaminergic neurons by inhibiting NADPH oxidase and iNOS in the MPTP model of Parkinson's disease. Ren B; Zhang YX; Zhou HX; Sun FW; Zhang ZF; Wei Z; Zhang CY; Si DW J Neurol Sci; 2015 Jan; 348(1-2):142-52. PubMed ID: 25491263 [TBL] [Abstract][Full Text] [Related]
12. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. Wu DC; Jackson-Lewis V; Vila M; Tieu K; Teismann P; Vadseth C; Choi DK; Ischiropoulos H; Przedborski S J Neurosci; 2002 Mar; 22(5):1763-71. PubMed ID: 11880505 [TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease. Ghosh A; Kanthasamy A; Joseph J; Anantharam V; Srivastava P; Dranka BP; Kalyanaraman B; Kanthasamy AG J Neuroinflammation; 2012 Oct; 9():241. PubMed ID: 23092448 [TBL] [Abstract][Full Text] [Related]
14. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum. Kawasaki T; Ishihara K; Ago Y; Baba A; Matsuda T J Pharmacol Exp Ther; 2007 Jul; 322(1):274-81. PubMed ID: 17429058 [TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. Delgado M; Ganea D FASEB J; 2003 May; 17(8):944-6. PubMed ID: 12626429 [TBL] [Abstract][Full Text] [Related]
16. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress. Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333 [TBL] [Abstract][Full Text] [Related]
17. Norfluoxetine Prevents Degeneration of Dopamine Neurons by Inhibiting Microglia-Derived Oxidative Stress in an MPTP Mouse Model of Parkinson's Disease. Kim KI; Chung YC; Jin BK Mediators Inflamm; 2018; 2018():4591289. PubMed ID: 30692871 [TBL] [Abstract][Full Text] [Related]
18. FTY720 Inhibits MPP Yao S; Li L; Sun X; Hua J; Zhang K; Hao L; Liu L; Shi D; Zhou H J Neuroimmune Pharmacol; 2019 Sep; 14(3):478-492. PubMed ID: 31069623 [TBL] [Abstract][Full Text] [Related]
19. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease. Wang S; Jing H; Yang H; Liu Z; Guo H; Chai L; Hu L J Ethnopharmacol; 2015 Apr; 164():247-55. PubMed ID: 25666429 [TBL] [Abstract][Full Text] [Related]
20. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Price DA; Martinez AA; Seillier A; Koek W; Acosta Y; Fernandez E; Strong R; Lutz B; Marsicano G; Roberts JL; Giuffrida A Eur J Neurosci; 2009 Jun; 29(11):2177-86. PubMed ID: 19490092 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]